CardioGen-82 is said to be the only generator-based positron emission tomography (PET) perfusion agent approved by the FDA and reimbursed for the evaluation of coronary artery disease.
CardioGen-82 PET myocardial perfusion imaging has experienced double digit year-over-year growth since 2003. It is expected that this agreement will further accelerate the rapid expansion of this modality.
Don Kiepert, president and CEO of Lantheus Medical Imaging, said: “This co-promotion agreement is a strategic fit for Lantheus and demonstrates our continued commitment to advancing the field of diagnostic imaging through our distribution network, customer service and sales and medical affairs field organization.”